Vilya launches with $50 million Series A

A biotechnology company aimed at creating a new class of medicines that precisely target disease biology, Vilya, has announced its launch with $50 million in committed Series A financing led by ARCH Venture Partners.

The funding will be used to advance the USA-based company’s proprietary platform, powered by machine learning, which can be used to design molecular structures that range in size between small molecules and antibodies, with critical drug-like properties, including the ability to move through biological membranes and to disrupt protein-to-protein interactions. These new artificial molecules can be leveraged for previously difficult-to-drug therapeutic targets in a broad set of indications.